<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356872</url>
  </required_header>
  <id_info>
    <org_study_id>SAIS</org_study_id>
    <nct_id>NCT04356872</nct_id>
  </id_info>
  <brief_title>The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma</brief_title>
  <official_title>A Single Arm, Multi Centers, Phase II Study of Sintilimab, Doxorubicin and Ifosfamide at First-line Treatment of Soft Tissue Sarcoma Including Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, Myxoid Liposarcoma and De-differentiated Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor,
      sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected
      soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate, ORR</measure>
    <time_frame>up to two years</time_frame>
    <description>the best response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival, PFS</measure>
    <time_frame>up to three years</time_frame>
    <description>from first dose treatment to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events, AE</measure>
    <time_frame>up to three years</time_frame>
    <description>treatment related adverse events, TRAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival, OS</measure>
    <time_frame>up to three years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PD-L1 expression</measure>
    <time_frame>up to two years</time_frame>
    <description>PD-L1 expression will be detected by Immunohistologic chemistry, IHC or PCR method</description>
  </other_outcome>
  <other_outcome>
    <measure>tumor infiltrating lymphocytes measurement</measure>
    <time_frame>up to two years</time_frame>
    <description>tumor infiltrating lymphocytes will be measured by flowcytometry using tissue and/or peripheral blood sample；</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with metastatic and unresectable soft tissue sarcoma including undifferentiated pleomorphic sarcoma, synovial sarcoma, de-differentiated liposarcoma and myxoid liposarcoma will be enrolled and given sintilimab (PD-1) , doxorubicin and doxorubicin every three weeks for 6 cycles followed by sintilimab mono therapy till disease progression. The first enrolled six patients is safety run-in step for observing drug-limiting toxicity (DLTs). If the combinatory treatment is intolerable, the doses of chemo regimens will be reduced according to drug instruction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>immune check point inhibitor, 200mg, iv, d1</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>ADM, 60mg/m2, iv, d1</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>ADM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>IFO, 1.8 g/m2/d, d1-5</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>IFO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18-75 years;

          -  Provide written informed consent;

          -  Local advanced or metastatic unresectable sarcoma;

          -  Histologically confirmed undifferentiated pleomorphic sarcoma, synovial sarcoma,
             de-differentiated liposarcoma and myxoid liposarcoma;

          -  Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG)
             performance scale;

          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1;

          -  Life span expectation over 3 months

          -  Absolute neutrophil count (ANC) ≥1,500/mcL (within 7 days of treatment initiation) ；

          -  Hemoglobin ≥9 g/dL (within 7 days of treatment initiation) ；

          -  Platelets ≥ 90,000/mcL (within 7 days of treatment initiation) ；

          -  Serum creatinine ≤ 1.5 X upper limit of normal (ULN) or creatinine clearance [CrCl]) ≥
             50 mL/min for subject with creatinine levels (within 7 days of treatment initiation) ；

          -  Serum total bilirubin ≤ 1.5 X ULN (within 7 days of treatment initiation) ；

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 X
             ULN or =&lt; 5 X ULN for subjects with liver metastases (within 7 days of treatment
             initiation)；

        Exclusion Criteria:

          -  Prior systemic therapy for advanced and metastatic disease, except adjuvant
             treatment（not received anthracycline）replase over 6 months;

          -  Received any testing anti-cancer drugs within four weeks of treatment initiation;

          -  Prior immune related therapy including but not limited to PD-1, PD-L1, CD137, CTLA4, T
             cell stimulation, check point inhibitor etc;

          -  Symptomatic, untreated, or uncontrolled brain metastases present

          -  clinical meaningful active bleeding;

          -  Other malignant cancer history rather than soft tissue sarcoma within five year prior
             to treatment initiation;

          -  Have active infections requiring therapy;

          -  Have active autoimmune disease or a documented history of autoimmune disease or
             syndrome that requires systemic steroids or immunosuppressive agents. Patients that
             require inhaled steroids or local steroid injections would not be excluded from the
             study. Patients with hypothyroidism not from autoimmune disease that is stable on
             hormone replacement will not be excluded from the study.

          -  Pregnant or breast-feeding；

          -  Any serious or unstable medical condition or mental illness；

          -  Serious systemic diseases such as heart disease, history of (non-infectious)
             pneumonitis;

          -  Active HBV （＞10000 copy/ml） and HCV （RNA&gt; 1000copy/ml） infection；

          -  Positive human immunodeficiency virus (HIV）or any acquired immunodeficiency syndrome,
             organ implantation;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Liu, MD</last_name>
    <phone>0086-021-64175590</phone>
    <email>jeanettexin@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University, Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Liu, MD</last_name>
      <phone>0086-18017317720</phone>
      <email>jeanettexin@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhiguo Luo, MD, PhD</investigator_full_name>
    <investigator_title>Chief Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>ifosfamide</keyword>
  <keyword>first line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>not yet decide, need to discuss with all collaborators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

